Michael Rosenblatt - Merck Insider

Executive Vice President Chief Medical Officer

Dr. Michael Rosenblatt, M.D., is Executive Vice President, Chief Medical Officer of Merck Co., Inc. He is responsible for the Companys primary voice to the global medical community on critical issues such as patient safety and oversight for the Companys Global Center for Scientific Affairs. Prior to December 2009, Dr. Rosenblatt was the Dean of Tufts University School of Medicine since 2003.
Age: 67  President Since 2009  Ph.D    
908 735-1500  www.merck.com

Management Efficiency

The company has Return on Asset of 6.58 % which means that on every $100 spent on asset it made $6.58 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 10.4 % implying that it generated $10.4 on every 100 dollars invested.
The company has 28.51 B in debt with debt to equity (D/E) ratio of 71.1 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck Co Inc has Current Ratio of 1.56 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


JeanYves PaveeAbbott Laboratories
Jonathon KellermanAllergan plc
Michael WarmuthAbbott Laboratories
Terrance CoughlinEndo International plc
Robert FordAbbott Laboratories
Roger BirdAbbott Laboratories
Georges VosAbbott Laboratories
Heather MasonAbbott Laboratories
Shannon HallBio Rad Laboratories Inc
Shawn SoderbergBio Rad Laboratories Inc
Philippe SchaisonAllergan plc
William MeuryAllergan plc
Ronald HuttonBio Rad Laboratories Inc
Michael PartridgeVertex Pharmaceuticals Incorpor
J WhiteAbbott Laboratories
Camille FarhatEndo International plc
Scott WhiteAbbott Laboratories
Paul SilvaVertex Pharmaceuticals Incorpor
John HertiaBio Rad Laboratories Inc
Michael PariniVertex Pharmaceuticals Incorpor
Michael McDonnellQuintiles IMS Holdings Inc

Entity Summary

Merck & Co., Inc. offer healthcare solutions worldwide. Merck Co Inc (MRK) is traded on New York Stock Exchange in USA. It is located in NEW JERSEY, U.S.A and employs 66,645 people. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Merck Co Inc to your portfolio

Top Management

Merck Co Inc Leadership Team
Thomas Glocer, Director
C Kidder, Director
Craig Thompson, Director
Rochelle Lazarus, Director
Michael Rosenblatt, President, Ph.D
Wendell Weeks, Director
Michael Holston, President
Paul Rothman, Director
Adele Ambrose, President
Joseph Romanelli, Executive
Mirian GraddickWeir, President, Ph.D
Peter Wendell, Director
Leslie Brun, Director
Julie Gerberding, President
Pamela Craig, Director, MBA
Patricia Russo, Director
Willie Deese, President
Rita Karachun, SVP
Robert Davis, CFO
Robert Kidder, Director
Thomas Cech, Director, Ph.D
Clark Golestani, EVP
William Harrison, Director
Bruce Kuhlik, EVP
Roger Perlmutter, President, Ph.D
Sanat Chattopadhyay, President
Adam Schechter, President
Carlos Represas, Director
Richard DeLuca, President
Kenneth Frazier, Chairman

Stock Performance

Merck Performance Indicators